CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells.
Saved in:
| Title: | CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. |
|---|---|
| Authors: | Naito M; Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA, USA., Hainz U, Burkhardt UE, Fu B, Ahove D, Stevenson KE, Rajasagi M, Zhu B, Alonso A, Witten E, Matsuoka K, Neuberg D, Duke-Cohan JS, Wu CJ, Freeman GJ |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2013 Feb; Vol. 62 (2), pp. 347-57. Date of Electronic Publication: 2012 Aug 25. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
